Targeting Anaplastic Lymphoma Kinase in Lung CancerSHAW, Alice T; SOLOMON, Benjamin.Clinical cancer research (Print). 2011, Vol 17, Num 8, pp 2081-2086, issn 1078-0432, 6 p.Article

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic StrategiesLOVLY, Christine M; SHAW, Alice T.Clinical cancer research (Print). 2014, Vol 20, Num 9, pp 2249-2256, issn 1078-0432, 8 p.Article

One Allele's Loss Is Another's Gain: Alterations of NKX2―8 in Non―Small Cell Lung CancerNEAL, Joel W; SHAW, Alice T.Clinical cancer research (Print). 2011, Vol 17, Num 4, pp 638-639, issn 1078-0432, 2 p.Article

Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung CancerGAINOR, Justin F; SHAW, Alice T.Journal of clinical oncology. 2013, Vol 31, Num 31, pp 3987-3996, issn 0732-183X, 10 p.Article

Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non―Small Cell Lung Cancer?CRYSTAL, Adam S; SHAW, Alice T.Clinical cancer research (Print). 2012, Vol 18, Num 17, pp 4479-4481, issn 1078-0432, 3 p.Article

Crizotinib in ROS1-Rearranged Non―Small-Cell Lung CancerSHAW, Alice T; OU, Sai-Hong I; DOEBELE, Robert C et al.The New England journal of medicine. 2014, Vol 371, Num 21, pp 1963-1971, issn 0028-4793, 9 p.Article

A Man with ALK-Positive Adenocarcinoma of the LungSHAW, Alice T; FORCIONE, David G; DIGUMARTHY, Subba R et al.The New England journal of medicine. 2011, Vol 365, Num 2, pp 158-167, issn 0028-4793, 10 p.Article

Ceritinib in ALK-Rearranged Non―Small-Cell Lung CancerSHAW, Alice T; KIM, Dong-Wan; RIELY, Gregory J et al.The New England journal of medicine. 2014, Vol 370, Num 13, pp 1189-1197, issn 0028-4793, 9 p.Article

ALK in Lung Cancer: Past, Present, and FutureSHAW, Alice T; ENGELMAN, Jeffrey A.Journal of clinical oncology. 2013, Vol 31, Num 8, pp 1105-1111, issn 0732-183X, 7 p.Article

Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALKSHAW, Alice T; YEAP, Beow Y; SETTLEMAN, Jeffrey et al.Journal of clinical oncology. 2009, Vol 27, Num 26, pp 4247-4253, issn 0732-183X, 7 p.Article

ROS1 Rearrangements Define a Unique Molecular Class of Lung CancersBERGETHON, Kristin; SHAW, Alice T; MARK, Eugene J et al.Journal of clinical oncology. 2012, Vol 30, Num 8, pp 863-870, issn 0732-183X, 8 p.Article

Acquired Resistance to Crizotinib from a Mutation in CD74―ROS1AWAD, Mark M; KATAYAMA, Ryohei; WILNER, Keith D et al.The New England journal of medicine. 2013, Vol 368, Num 25, pp 2395-2401, issn 0028-4793, 7 p.Article

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung CancerSHAW, Alice T; KIM, Dong-Wan; WU, Yi-Long et al.The New England journal of medicine. 2013, Vol 368, Num 25, pp 2385-2394, issn 0028-4793, 10 p.Article

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-mall Cell Lung CancerGAINOR, Justin F; VARGHESE, Anna M; LAFRATE, A. John et al.Clinical cancer research (Print). 2013, Vol 19, Num 15, pp 4273-4281, issn 1078-0432, 9 p.Article

Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung CancerKWAK, Eunice L; BANG, Yung-Jue; VARELLA-GARCIA, Marileila et al.The New England journal of medicine. 2010, Vol 363, Num 18, pp 1693-1703, issn 0028-4793, 11 p.Article